SCHEMBL17021339

SCHEMBL17021339

CC(c1ccc(Nc2cc(NCc3cccc(F)c3)c(C(N)=O)nn2)cc1)S(C)(=O)=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDC7 O00311 1/20 0.41
▸ ROCK2 O75116 1/20 0.41
▸ MAP4K4 O95819 1/20 0.41
▸ PIM1 P11309 1/20 0.41
▸ CDK2 P24941 1/20 0.41
▸ GSK3B P49841 1/20 0.41
▸ CLK4 Q9HAZ1 1/20 0.41
▸ JAK3 P52333 5/20 0.41
▸ NTRK1 P04629 2/20 0.41
▸ RPS6KB1 P23443 5/20 0.41
▸ JAK2 O60674 3/20 0.40
▸ JAK1 P23458 3/20 0.40
▸ IRAK4 Q9NWZ3 2/20 0.40
▸ TYK2 P29597 2/20 0.40
▸ FFAR1 O14842 1/20 0.39
▸ AURKA O14965 3/20 0.39
▸ AURKB Q96GD4 1/20 0.39
▸ SYK P43405 2/20 0.39
▸ KCNH2 Q12809 1/20 0.39
▸ STAT6 P42226 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19010328 0.92 FFAR1 (0.40) CDC7ROCK2MAP4K4PIM1CDK2
SCHEMBL17021366 0.88 JAK3 (0.44) CDC7ROCK2MAP4K4PIM1CDK2
SCHEMBL17021356 0.87 CDC7 (0.43) CDC7ROCK2MAP4K4PIM1CDK2
SCHEMBL17021380 0.86 FFAR1 (0.44) CDC7ROCK2MAP4K4PIM1CDK2
SCHEMBL17021355 0.85 JAK3 (0.41) CDC7ROCK2MAP4K4PIM1CDK2
SCHEMBL17021363 0.85 PTK2 (0.45) CDC7ROCK2MAP4K4PIM1CDK2
SCHEMBL17021375 0.84 JAK3 (0.44) CDC7ROCK2MAP4K4PIM1CDK2
SCHEMBL17021312 0.82 NTRK1 (0.47) CDC7ROCK2MAP4K4PIM1CDK2
SCHEMBL17021367 0.81 RPS6KB1 (0.43) CDC7ROCK2MAP4K4PIM1CDK2
SCHEMBL17021379 0.81 CDC7 (0.42) CDC7ROCK2MAP4K4PIM1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9834548-B2 Pyridazine compounds as JAK inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2017-12-05 — — US disclosed
US-9834548-B2 Pyridazine compounds as JAK inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2017-12-05 — — US disclosed
US-20170174673-A1 PYRIDAZINE COMPOUNDS AS JAK INHIBITORS ALEXION PHARMACEUTICALS, INC. 2017-06-22 — — US disclosed
US-20170174673-A1 PYRIDAZINE COMPOUNDS AS JAK INHIBITORS ALEXION PHARMACEUTICALS, INC. 2017-06-22 — — US disclosed
WO-2015123453-A1 PYRIDAZINE COMPOUNDS AS JAK INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2015-08-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174673-A1 PYRIDAZINE COMPOUNDS AS JAK INHIBITORS JAK1, JAK2, JAK3 CDC7 815/4885ROCK2 520/4885MAP4K4 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback